CoChat

The Omnipresence of DYRK1A in Human Diseases

Open access
Deboever, Estelle, Fistrovich, Alessandra, Hulme, Christopher, Dunckley, Travis · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.

Abstract

The increasing population will challenge healthcare, particularly because the worldwide population has never been older. Therapeutic solutions to age-related disease will be increasingly critical. Kinases are key regulators of human health and represent promising therapeutic targets for novel drug candidates. The dual-specificity tyrosine-regulated kinase (DYRKs) family is of particular interest and, among them, DYRK1A has been implicated ubiquitously in varied human diseases. Herein, we focus on the characteristics of DYRK1A, its regulation and functional role in different human diseases, which leads us to an overview of future research on this protein of promising therapeutic potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23169355

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 DYRK family of proteins origins and specificities in humans (based on [10,14,15,16,17,18,19,20]). The percentage of conservation at the protein level between orthologues is indicated above the arrows and between two paralogues is indicated in parentheses within the boxes.
Figure 1 DYRK family of proteins origins and specificities in humans (based on [10,14,15,16,17,18,19,20]). The percentage of conservation at the protein level between orthologues is indicated above the arrows and between two paralogues is indicated in parentheses within the boxes.CC BY · PubMed Central
Figure 2 Schematic representation of the protein sequences of the 5 human DYRKs (from uniport.org and based on [10,24]). The different protein motifs identified are indicated: NLS, nuclear localization signal; DH, DYRK-homology box; NAPA, N-terminal autophosphorylation accessory region; kinase, kinase domain; PEST, motif rich in proline, glutamic acid, serine, and threonine residues; His, polyhistidine domain; S/T, serine and threonine-enriched domain; and Y, tyrosine residue autophosphorylated by DYRKs within the activation loop. Turquoise lines indicate protein regions affected by alternative splicing events.
Figure 2 Schematic representation of the protein sequences of the 5 human DYRKs (from uniport.org and based on [10,24]). The different protein motifs identified are indicated: NLS, nuclear localization signal; DH, DYRK-homology box; NAPA, N-terminal autophosphorylation accessory region; kinase, kinase domain; PEST, motif rich in proline, glutamic acid, serine, and threonine residues; His, polyhistidine domain; S/T, serine and threonine-enriched domain; and Y, tyrosine residue autophosphorylated by DYRKs within the activation loop. Turquoise lines indicate protein regions affected by alternative splicing events.CC BY · PubMed Central
Figure 3 Schematic representation of the spectrum of action of a DYRK1A activator or inhibitor on the development of neurological (in green) and other diseases (in brown) in humans. Pathologies are labeled with a green cross if DYRK1A activation is a potential therapeutic solution and with a red line if DYRK1A inhibition is a potential solution.
Figure 3 Schematic representation of the spectrum of action of a DYRK1A activator or inhibitor on the development of neurological (in green) and other diseases (in brown) in humans. Pathologies are labeled with a green cross if DYRK1A activation is a potential therapeutic solution and with a red line if DYRK1A inhibition is a potential solution.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 144 references

Cited by

See all 83

Metadata

Authors
Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T.
Affiliations
  • Arizona State University (US)
  • University of Arizona (US)
Corresponding author
  • Deboever, Estelle
  • Dunckley, Travis
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-08-19
Volume
23
Issue
16
Pages
9355
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4293678299
Cited by
77
References
143
Citations by year
2026: 20 · 2025: 26 · 2024: 20 · 2023: 11
FWCI
2.38
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Edson Family Foundation (38526, 1R01NS109422-01A1)
  • NIA grant (38526, 1R01NS109422-01A1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
DYRK1A, kinases, age-related diseases, therapeutic target, kinase regulation, human disease, drug candidates
MeSH terms
Dyrk Kinases, Disease, Humans, Protein-Tyrosine Kinases, Protein Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Omnipresence of DYRK1A in Human Diseases. https://app.cochat.ai/papers/10.3390/ijms23169355
The paper
Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T. (2022). The Omnipresence of DYRK1A in Human Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23169355

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.